UK & Ireland, experts provided insights on market trends within the clinical trial industry and advice on engagement strategies.

LEO Pharma has reported outcomes from the 16-week interim analysis of the Phase IIIb ADHAND trial of tralokinumab for hand atopic dermatitis (AD).

The US FDA has approved Purespring Therapeutics’ IND application for PS-002, allowing the company to begin a Phase I/II trial.

Artificial intelligence (AI) should soon be taking a greater role in areas including patient recruitment and in building efficiencies around data quality.